73 related articles for article (PubMed ID: 19145672)
61. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
62. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G
Anticancer Res; 2013 Jun; 33(6):2743-6. PubMed ID: 23749935
[TBL] [Abstract][Full Text] [Related]
63. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
64. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
65. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
66. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.
Vrdoljak E; Omrcen T; Boban M; Hrepic D
J BUON; 2008; 13(4):513-8. PubMed ID: 19145672
[TBL] [Abstract][Full Text] [Related]
67.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
68.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
69.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
70.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
71.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
72.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]